echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Yiteng pharmaceutical and Ablynx reached a cooperation agreement on the nanotherapy antibody alx-0141 for osteoporosis

    Yiteng pharmaceutical and Ablynx reached a cooperation agreement on the nanotherapy antibody alx-0141 for osteoporosis

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    On October 14, 2013, Yiteng pharmaceutical, a fast-growing professional pharmaceutical company in China, announced a cooperation with Ablynx pharmaceutical

    Yiteng pharmaceutical was authorized by Ablynx pharmaceutical to develop, register and commercialize its nano antibody product alx-0141 in mainland China, Hong Kong, Macao and Taiwan, which is mainly used for indications such as osteoporosis and cancer bone metastasis

    Ablynx Pharmaceutical Co., Ltd

    is an internationally renowned nano antibody R & D pharmaceutical company

    Yiteng pharmaceutical and Ablynx pharmaceutical will greatly meet the growing demand of China's osteoporosis prevention and control market


    Ni Xin, chairman and CEO of Yiteng pharmaceutical, said that he was very pleased to accept the entrustment of Ablynx pharmaceutical to develop and commercialize anti RANKL nano antibody products in Greater China

    "We will work hand in hand with Ablynx to deliver innovative drugs and health to a wide range of Chinese patients," he said

    Regarding the cooperation with Yiteng pharmaceutical, Mr

    Edwin Moses, chairman of Ablynx pharmaceutical, praised that "Yiteng pharmaceutical has the best conditions to further develop and commercialize alx0141 in the Greater China region, and the product has achieved rapid growth in the field of bone related diseases

    We are very looking forward to working together with Yiteng pharmaceutical, and will give Yiteng the greatest support in the follow-up development process of products and commercialization! " At present, the number of people suffering from osteoporosis is increasing year by year

    With the increasing trend of population aging, the improvement of people's living standards and the strengthening of bone health awareness, the osteoporosis prevention and treatment market is experiencing an unprecedented explosive growth

    According to the latest research report released by transparency market, the compound growth rate of China's osteoporosis drug market from 2010 to 2015 will reach 13.5% to US $2.5 billion

    It is reported that the nano antibody drugs of Ablynx pharmaceutical have significant safety and many characteristics with good efficacy for the detection of biomarkers, which make it have great potential in related fields

    Alx-0141 is a new product for bone diseases

    According to the results of a clinical test for healthy menopausal women, the single administration of alx0141 has a strong and long-term inhibitory effect on bone resorption biomarkers

    The patient was well tolerated without serious side effects or toxic reactions due to dose limitation.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.